The present study is based on a retrospective analysis of Gallium-68 (68Ga)-labelled prostate-specific membrane antigen (68Ga-PSMA I&T) PET/CT performed in newly diagnosed, treatment-naïve prostate cancer (PCa) patients prior to definitive treatment. A total of 82 men were included in the study and were imaged with 68Ga-PSMA I&T PET/CT to assess the distribution of PSMA-avid disease […]
Testosterone level of < 50 ng/dL has been used to define castrate level after surgery or after androgen deprivation treatment (ADT) in metastatic prostate cancer (PC). To evaluate the effect of two different castrate testosterone levels, < 50 and < 20 ng/dL, on biochemical relapse free survival (BRFS) in patients with non-metastatic intermediate and high […]
Prostate-specific membrane antigen (PSMA) is a transmembrane protein that is highly expressed on the surface of prostate cancer (PC) cells, making it an excellent radiotracer for both therapeutic and diagnostic purposes. In this prospective study, we investigated the efficacy and toxicity of 177Lutetium (Lu)-PSMA in metastatic castration-resistant PC (mCRPC) patients for the establishment and approval […]
To personalize treatment for renal cell carcinoma (RCC), it would be ideal to confirm the activity of druggable protein pathways within individual tumors. We have developed a high-resolution nanoimmunoassay (NIA) to measure protein activity with high precision in scant specimens (eg, fine needle aspirates [FNAs]). Here, we used NIA to determine whether protein activation varied […]
Nivolumab plus ipilimumab (NIVO+IPI) demonstrated superior efficacy over sunitinib (SUN) for previously untreated advanced renal cell carcinoma (aRCC) in CheckMate 214, with a manageable safety profile. We report efficacy and safety with extended follow-up amongst Japanese patients. CheckMate 214 patients received NIVO (3 mg/kg) plus IPI (1 mg/kg) every 3 weeks for four doses, then NIVO (3 mg/kg) every […]
Athens, Greece (Urotoday.com) In today’s medical environment of the growing number of patients, increasing complexity of patient problems, an ever-growing body of literature and available data, with limited time and increasing human error and bias, the need for artificial intelligence is at its peak. Human error is part of life in every field, including medicine, […]
Athens, Greece (Urotoday.com) Dr. Laurence Klotz presented on how to reduce scientific error and ensuring innovation. The history of science is a history of irresponsible dreams, obstinacy, and error. But science is one of the very few human activities – perhaps the only one – in which errors are systematically criticized and often corrected. In science, […]
Athens, Greece (Urotoday.com) Dr. Kamat gave a talk on the extent of lymph node dissection for bladder cancer. First, it is important to note that patients with negative lymph nodes do not benefit from pelvic lymph nodes removal, as removal of normal nodes is not helpful. Those that do benefit are a subset of patients with […]
Athens, Greece (Urotoday.com) Oncofid-P-B is a conjugate of paclitaxel and Hyaluronic acid (HA) for the treatment of non-muscle-invasive bladder cancer (NMIBC) by intravesical instillation. This conjugate confers tumor-targeted activity, improves paclitaxel solubility, reduces paclitaxel toxicity, and confers mucoadhesive properties. A phase 1 study with multiple escalating doses (150-750 mg for 6 weeks) in 16 BCG refractory […]
Athens, Greece (Urotoday.com) Dr. Ashish Kamat gave a brief overview of enhanced recovery after surgery (ERAS) in patients undergoing radical cystectomy and provided some data on the comparison of robotic and open radical cystectomy. In the past, before the implementation of the ERAS pathway, surgery was planned “as soon as possible,” with no training or conditioning of […]
